IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by PFG Advisors

PFG Advisors grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 39.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 10,375 shares of the company's stock after purchasing an additional 2,910 shares during the quarter. PFG Advisors' holdings in IDEXX Laboratories were worth $4,357,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also modified their holdings of IDXX. Norges Bank bought a new stake in IDEXX Laboratories in the fourth quarter valued at about $412,258,000. GAMMA Investing LLC grew its holdings in IDEXX Laboratories by 59,810.7% during the first quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock worth $3,856,950,000 after purchasing an additional 916,898 shares during the period. Principal Financial Group Inc. grew its holdings in IDEXX Laboratories by 58.3% during the first quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock worth $472,865,000 after purchasing an additional 414,802 shares during the period. Alyeska Investment Group L.P. acquired a new stake in IDEXX Laboratories during the fourth quarter worth approximately $156,412,000. Finally, BNP Paribas Financial Markets raised its position in shares of IDEXX Laboratories by 221.3% in the fourth quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company's stock valued at $182,459,000 after buying an additional 303,966 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Leerink Partners increased their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price objective on the stock. Stifel Nicolaus upped their target price on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a research note on Wednesday, July 2nd. Wall Street Zen raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Finally, Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $560.33.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director owned 1,801 shares of the company's stock, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Up 1.5%

Shares of IDEXX Laboratories stock opened at $522.29 on Tuesday. The firm's 50 day moving average price is $523.58 and its 200-day moving average price is $463.41. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $549.52. The company has a market cap of $42.00 billion, a P/E ratio of 48.25, a PEG ratio of 3.74 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. IDEXX Laboratories's revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.71 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.